Olivier MANSIER PharmD, PhD

Course and current status

I studied in the field of pharmacy in Clermont-Ferrand before moving to Bordeaux for my internship in Medical Biology in 2009. I chose to specialize in biological hematology. Between 2012 and 2017, I trained in fundamental research under the supervision of Dr Eric Lippert and Pr François-Xavier Mahon.

Since November 2017, I have joined the laboratory of hematology of the university hospital of Bordeaux and the research group of Pr Chloe James (INSERM U1034, head Pr Thierry Couffinhal).

Scientific summary

During the last 10 years, I have been working in onco-hematology, with a particular interest in myeloproliferative neoplasms (MPN). In these diseases, molecular biology is of great importance for the diagnosis, characterization and follow-up of patients. In particular, I contributed to the characterization of patients with low allelic JAK2V617F burden and to the development of new molecular techniques based on digital PCR to monitor residual disease.

During my PhD, I focused on the study of endoplasmic reticulum biology in MPN, leading to the description of the mechanisms involved in the degradation of oncogenic CALR mutant proteins.

In 2017, I joined the laboratory of hematology of the university hospital of Bordeaux, in the department of Genetics of hematological malignancies. I am involved in the molecular testing of patients with acute and chronic myeloid hematological malignancies. I also contribute to the development of new techniques of molecular biology to improve our routine practice.

At the same time, I joined the research group of Pr Chloe James (INSERM unit U1034, head Pr T Couffinhal) specialized in the study of thrombosis associated with MPN. The recent description of the association between clonal hematopoiesis of indeterminate potential (CHIP) with cardiovascular events raised my interest. Taking advantage of my expertise in molecular testing of hematological malignancies, I now focus on investigating genetic and epigenetic events occurring in hematopoietic cells during aging that could be involved in the occurrence of atherosclerosis and thrombosis in MPN and/or CHIP.

Image d’exemple